Preoperative Pazopanib in High-Risk Soft Tissue Sarcoma: Phase II Window-of Opportunity Study of the German Interdisciplinary Sarcoma Group (NOPASS/GISG-04)

ISSN
1068-9265
Date Issued
2019-05
Author(s)
Ronellenfitsch, Ulrich
Karampinis, Ioannis
Dimitrakopoulou-Strauss, Antonia
Sachpekidis, Christos
Kasper, Bernd
Nowak, Kai
Pilz, Lothar
Attenberger, Ulrike
Gaiser, Timo
Derigs, Hans-Günther
Schwarzbach, Matthias
Hohenberger, Peter
DOI
10.1245/s10434-019-07183-4
Abstract
Preoperative devascularization might improve local control and thus the outcome of patients with soft tissue sarcoma (STS). The multikinase inhibitor pazopanib has antiangiogenic effects and is approved for treating metastatic STS. We conducted a trial of preoperative pazopanib therapy in high-risk STS.